Amarin (NASDAQ:AMRN) Announces Earnings Results

Amarin (NASDAQ:AMRN - Get Free Report) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.02, Yahoo Finance reports. The company had revenue of $56.52 million for the quarter, compared to analyst estimates of $51.34 million. Amarin had a negative return on equity of 10.47% and a negative net margin of 19.26%. During the same period in the prior year, the firm posted ($0.04) EPS.

Amarin Stock Up 9.4 %

Amarin stock traded up $0.08 during trading hours on Thursday, hitting $0.92. The stock had a trading volume of 1,479,096 shares, compared to its average volume of 1,940,914. The stock has a market cap of $377.00 million, a price-to-earnings ratio of -6.39 and a beta of 1.95. The business's 50 day simple moving average is $0.95 and its 200-day simple moving average is $0.94. Amarin has a one year low of $0.65 and a one year high of $1.49.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an "overweight" rating on shares of Amarin in a research report on Friday, January 12th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $1.08.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.